Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2016) 4","Short Ratio (Jun 14, 2016) 4","Short % of Float (Jun 14, 2016) 4","Short % of Shares Outstanding (Jun 14, 2016) 4","Shares Short (prior month May 12, 2016) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ECTE,-6634456.0,12004300,588551,,794171,,794171,736328,0,-1351804,-1351804,,-1067851,,,,0,0,1351804,0,2145975,,794171,794171,267811.0,148414835.0,7362894.0,-6366645.0,1010694.0,1076507.0,116358.0,-154897838.0,95535.0,217806.0,172725.0,7267359.0,188936.0,401954.0,1851043.0,282942.0,-27588.0,122959.0,122959.0,635260.0,-765936.0,-861307.0,26925.0,-64.0,-3535399.0,-6354.0,,-6865405.0,en-US,US,EQUITY,False,Delayed Quote,100,0.0,0.0,1.0E-4 - 0.28,-0.2799,-0.9996429,0.0001,0.28,-0.547,0.0006555556,-0.00055555557,-0.84745765,0.020003732,-0.019903732,24008,4,0.0,-0.00018281536,15,America/New_York,EDT,-14400000,1.0E-4 - 1.0E-4,0.0001,1.44,1.53,1,12,finmb_34553,Other OTC,"Echo Therapeutics, Inc.",USD,7362,USD,False,False,0.0001,1630425464,0.0,0.0002,0.0001,0.0001,500,PNK,ECHO THERAPEUTICS INC,0,us_market,REGULAR,-1.102,-0.99500096,6.99,,,0.28,0.0001,0.0007,0.02,7.36k,100,12M,,10.83M,0.00%,0.00%,273.27k,3.4,2.40%,2.40%,202.15k,,,,,,0.00%,,,1:10,"Jun 06, 2013","Dec 30, 2015","Sep 29, 2016",0.00%,0.00%,-359.77%,,,,,,-5.18M,-12.5M,-1.1020,,172.72k,0.01,3.52M,,0.05,-0.55,-4.82M,-910.41k,Value,08830,Healthcare,19,"Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.",Iselin,732-201-4189,NJ,1451520000,United States,http://www.echotx.com,86400,99 Wood Avenue South,Medical Devices,Suite 302
t-1,ECTE,-7696408.0,12004300,665717,,-2940848,,-2940848,792761,0,-1485987,-1485987,,-817625,,,,0,0,1485987,0,-1454861,,-2940848,-9401666,242641.0,148123118.0,9244973.0,-7453767.0,4686520.0,1871464.0,115124.0,-155692009.0,95535.0,217742.0,938661.0,9149438.0,209507.0,1201574.0,1615339.0,-256751.0,-86107.0,2476437.0,2476437.0,141185.0,895832.0,-1494498.0,27509.0,-3466.0,824155.0,-6354.0,,-7947864.0,en-US,US,EQUITY,False,Delayed Quote,100,0.0,0.0,1.0E-4 - 0.28,-0.2799,-0.9996429,0.0001,0.28,-0.547,0.0006555556,-0.00055555557,-0.84745765,0.020003732,-0.019903732,24008,4,0.0,-0.00018281536,15,America/New_York,EDT,-14400000,1.0E-4 - 1.0E-4,0.0001,1.44,1.53,1,12,finmb_34553,Other OTC,"Echo Therapeutics, Inc.",USD,7362,USD,False,False,0.0001,1630425464,0.0,0.0002,0.0001,0.0001,500,PNK,ECHO THERAPEUTICS INC,0,us_market,REGULAR,-1.102,-0.99500096,6.99,,,0.28,0.0001,0.0007,0.02,7.36k,100,12M,,10.83M,0.00%,0.00%,273.27k,3.4,2.40%,2.40%,202.15k,,,,,,0.00%,,,1:10,"Jun 06, 2013","Dec 30, 2015","Sep 29, 2016",0.00%,0.00%,-359.77%,,,,,,-5.18M,-12.5M,-1.1020,,172.72k,0.01,3.52M,,0.05,-0.55,-4.82M,-910.41k,Value,08830,Healthcare,19,"Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.",Iselin,732-201-4189,NJ,1451520000,United States,http://www.echotx.com,86400,99 Wood Avenue South,Medical Devices,Suite 302
t-2,ECTE,-5011842.0,12004300,689018,,-2621228,,-2621228,936627,0,-1656301,-1656301,,-224153,,,,0,0,1656301,0,-964927,,-2621228,-2621228,160000.0,147785306.0,5757810.0,-4851842.0,1603239.0,986226.0,114013.0,-152751161.0,95535.0,214276.0,42829.0,5662275.0,237016.0,374934.0,1997741.0,-178345.0,-137601.0,1935851.0,1935851.0,-343971.0,-13381.0,-1811631.0,30656.0,22399.0,1116291.0,-6354.0,,-5287341.0,en-US,US,EQUITY,False,Delayed Quote,100,0.0,0.0,1.0E-4 - 0.28,-0.2799,-0.9996429,0.0001,0.28,-0.547,0.0006555556,-0.00055555557,-0.84745765,0.020003732,-0.019903732,24008,4,0.0,-0.00018281536,15,America/New_York,EDT,-14400000,1.0E-4 - 1.0E-4,0.0001,1.44,1.53,1,12,finmb_34553,Other OTC,"Echo Therapeutics, Inc.",USD,7362,USD,False,False,0.0001,1630425464,0.0,0.0002,0.0001,0.0001,500,PNK,ECHO THERAPEUTICS INC,0,us_market,REGULAR,-1.102,-0.99500096,6.99,,,0.28,0.0001,0.0007,0.02,7.36k,100,12M,,10.83M,0.00%,0.00%,273.27k,3.4,2.40%,2.40%,202.15k,,,,,,0.00%,,,1:10,"Jun 06, 2013","Dec 30, 2015","Sep 29, 2016",0.00%,0.00%,-359.77%,,,,,,-5.18M,-12.5M,-1.1020,,172.72k,0.01,3.52M,,0.05,-0.55,-4.82M,-910.41k,Value,08830,Healthcare,19,"Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.",Iselin,732-201-4189,NJ,1451520000,United States,http://www.echotx.com,86400,99 Wood Avenue South,Medical Devices,Suite 302
t-3,ECTE,-2606131.0,12004300,519260,,-1272715,,-1276135,395511,0,-949140,-949140,,-10405,,,,3420,0,949140,0,-323575,,-1276135,-1276135,,147412559.0,3330963.0,-2606131.0,127000.0,805090.0,111243.0,-150129933.0,95535.0,236675.0,56210.0,3235428.0,267671.0,300744.0,2176083.0,260583.0,-137601.0,573420.0,973420.0,-8891.0,52980.0,-920440.0,34369.0,22399.0,69634.0,-6354.0,400000.0,-2934684.0,en-US,US,EQUITY,False,Delayed Quote,100,0.0,0.0,1.0E-4 - 0.28,-0.2799,-0.9996429,0.0001,0.28,-0.547,0.0006555556,-0.00055555557,-0.84745765,0.020003732,-0.019903732,24008,4,0.0,-0.00018281536,15,America/New_York,EDT,-14400000,1.0E-4 - 1.0E-4,0.0001,1.44,1.53,1,12,finmb_34553,Other OTC,"Echo Therapeutics, Inc.",USD,7362,USD,False,False,0.0001,1630425464,0.0,0.0002,0.0001,0.0001,500,PNK,ECHO THERAPEUTICS INC,0,us_market,REGULAR,-1.102,-0.99500096,6.99,,,0.28,0.0001,0.0007,0.02,7.36k,100,12M,,10.83M,0.00%,0.00%,273.27k,3.4,2.40%,2.40%,202.15k,,,,,,0.00%,,,1:10,"Jun 06, 2013","Dec 30, 2015","Sep 29, 2016",0.00%,0.00%,-359.77%,,,,,,-5.18M,-12.5M,-1.1020,,172.72k,0.01,3.52M,,0.05,-0.55,-4.82M,-910.41k,Value,08830,Healthcare,19,"Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.",Iselin,732-201-4189,NJ,1451520000,United States,http://www.echotx.com,86400,99 Wood Avenue South,Medical Devices,Suite 302
